Dermatology, Drugs, Genome and Genomics - Clinical Research Informer

Sanofi wagers $400m on miRecule muscular dystrophy therapy

pharmaphorum

OCTOBER 5, 2022

The new drug candidate for FSHD will combine an RNA molecule from miRecule targeting double homeobox 4 (DUX4) – a protein that is mutated in FSHD – with a nanobody developed by Sanofi that targets muscle cells. .” billion deal in 2018. The aim will be to identify promising candidates in areas of “unmet patient need.”

RNA

RNA Genetics Dermatology Antibody

Novel drug combo activates natural killer cell immunity to destroy cancer cells

The Pharma Data

JUNE 19, 2022

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, they can wear out and cease to function. The team has identified a unique combination drug strategy to activate this natural killer cell-mediated immunity in mice.

Drugs

Drugs Protein Immune Response Dermatology

This week in drug discovery (12-16 December)

Drug Discovery World

DECEMBER 16, 2022

First AML patient successfully transplanted with investigational drug . The post This week in drug discovery (12-16 December) appeared first on Drug Discovery World (DDW).

Drugs

Drugs Vaccination Vaccine Genetics

Leading innovators in anti-viral antigen-based compositions for the pharmaceutical industry

Pharmaceutical Technology

MAY 8, 2023

Innovation S-curve for the pharmaceutical industry Anti-viral antigen-based compositions is a key innovation area in pharmaceuticals A viral antigen is a protein encoded by the viral genome that can be detected by a specific immunological response.

Antibody

Antibody Vaccination Vaccine Dermatology

Filsuvez Topical Gel Gets FDA Approval for Epidermolysis Bullosa

XTalks

JANUARY 2, 2024

Chiesi Global Rare Diseases, a specialized division within the Chiesi Group dedicated to pioneering therapies for individuals affected by rare diseases, has received approval from the US Food and Drug Administration (FDA) for Filsuvez (birch triterpenes) topical gel.

FDA Approval

FDA Approval Gene Therapy Gene Trials

Listen now: Last episode of DDW Highlights for 2022

Drug Discovery World

DECEMBER 19, 2022

You can listen below, or find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts. . The post Listen now: Last episode of DDW Highlights for 2022 appeared first on Drug Discovery World (DDW).

Genetics

Genetics Drugs Development Dermatology

The next generation of AI

Drug Discovery World

APRIL 15, 2024

Last year, a lot of focus was placed on artificial intelligence (AI) both outside of the life sciences sector, with the rise of Chat GPT, and inside, following a growing interest in the use of generative AI for drug discovery and development.

Antibody

Antibody Drugs In-Vivo Life Science

Clinical Catch-Up: January 18-22 | BioSpace

The Pharma Data

JANUARY 24, 2021

The drug appears to inhibit IL-6, IL-1beta, TNF-alpha and other pro-inflammatory cytokines and chemokines. The drug did not differ statistically from placebo at 48 weeks on the prespecified co-primary endpoints on the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 11 and the Clinical Dementia Rating Scale Sum of Boxes.

Trials

Trials Allergies In-Vitro Antibody

First Anti-PD-1 in Combination With Chemotherapy Approved for the First-Line Treatment of Esophageal and GEJ Carcinoma, Regardless of Histology or PD-L1 Expression

The Pharma Data

MARCH 23, 2021

Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation. KENILWORTH, N.J.–(BUSINESS

HR

HR FDA Approval Containment Genome

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Monotherapy Post-Sorafenib Hepatocellular Carcinoma U.S. Indication

The Pharma Data

JULY 23, 2021

Food and Drug Administration (FDA), Bristol Myers Squibb has made the difficult decision to voluntarily withdraw the indication for Opdivo (nivolumab) as a single agent for patients with hepatocellular carcinoma (HCC) who were previously treated with sorafenib from the U.S. endocrinopathies and dermatologic reactions) are discussed below.

Hormones

Hormones Trials Genome Genomics

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Hepatocellular Carcinoma U.S. Indication

The Pharma Data

MARCH 11, 2021

Food and Drug Administration (FDA) will hold a public meeting of the Oncologic Drugs Advisory Committee (ODAC) between April 27-29, 2021 to discuss accelerated approvals in oncology impacted as part of the Agency’s industry-wide review. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Trials

Trials Hormones Genome Genomics

FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)

The Pharma Data

JULY 8, 2021

Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with locally advanced cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. KENILWORTH, N.J.–(BUSINESS Head and Neck Squamous Cell Cancer.

FDA Approval

FDA Approval Containment Trials Genome

DermTech Announces Pricing of Public Offering of Common Stock – Jan 07, 2021

The Pharma Data

JANUARY 6, 2021

Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the pricing of its previously announced underwritten public offering of 4,237,288 shares of its common stock at a price to the public of $29.50 7, 2021 05:00 UTC. LA JOLLA, Calif.–(

Dermatology

Dermatology Genome Genomics Production

CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

The Pharma Data

AUGUST 11, 2020

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Immune-Mediated Skin and Dermatologic Adverse Reactions.

Trials

Trials Hormones Clinical Trials Clinical Trials

CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers

The Pharma Data

AUGUST 11, 2020

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Immune-Mediated Skin and Dermatologic Adverse Reactions.

Trials

Trials Hormones Clinical Trials Clinical Trials

Clinical Research Informer

Sanofi wagers $400m on miRecule muscular dystrophy therapy

Novel drug combo activates natural killer cell immunity to destroy cancer cells

Trending Sources

This week in drug discovery (12-16 December)

Leading innovators in anti-viral antigen-based compositions for the pharmaceutical industry

Filsuvez Topical Gel Gets FDA Approval for Epidermolysis Bullosa

Listen now: Last episode of DDW Highlights for 2022

The next generation of AI

Clinical Catch-Up: January 18-22 | BioSpace

First Anti-PD-1 in Combination With Chemotherapy Approved for the First-Line Treatment of Esophageal and GEJ Carcinoma, Regardless of Histology or PD-L1 Expression

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Monotherapy Post-Sorafenib Hepatocellular Carcinoma U.S. Indication

Bristol Myers Squibb Statement on Opdivo® (nivolumab) Hepatocellular Carcinoma U.S. Indication

FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)

DermTech Announces Pricing of Public Offering of Common Stock – Jan 07, 2021

CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers

Stay Connected